During the year, 316 listed companies implemented buybacks, and 32 pharmaceutical manufacturing companies

According to Tonghuashun iFinD statistics, as of September 15, 316 listed companies implemented repurchases, with a cumulative repurchase amount of 36.734 billion yuan.
In terms of industry distribution, it is mainly concentrated in the pharmaceutical manufacturing industry, computer, telecommunications and other electronic equipment manufacturing industry, electrical machinery and equipment manufacturing industry, chemical raw materials and chemicals manufacturing industry and other four major industries, respectively, 32, 23, 21 and 20 companies to implement repurchase.
32 pharmaceutical companies implemented repurchases, including 32 companies in the pharmaceutical manufacturing industry, including Lizhu Pharmaceuticals, Renfu Pharmaceuticals, Tianshili Pharmaceuticals, Jincheng Pharmaceuticals, Undelisted Pharmaceuticals, Yifan Pharmaceuticals, China Resources Pharmaceuticals, Asia Pacific Pharmaceuticals, Dongrui Pharmaceuticals, etc.
public information, in September alone, a number of companies implemented buybacks.
For example, on September 15, Toray Pharmaceuticals announced that it would repurchase 240,000 shares on the Hong Kong Stock Exchange on September 15, 2020 at a cost of HK$238.2 million, with an average repurchase price of about HK$0.99 based on the number and cost of the repurchase;
that the cumulative number of shares repurchased by Toray Pharmaceuticals in the past three months was 3.908 million shares, accounting for 0.25% of the company's issued share value.
On September 14, Shisyo Pharmaceutical Group announced that it would repurchase 50.00 million shares on the Hong Kong Stock Exchange on September 14, 2020 at a cost of HK$2.326 million, with an average repurchase price of about HK$4.65 based on the number and cost of the repurchase;
understood that Shisty Pharmaceutical Group in the past three months accumulated repurchase of shares of 106.78 million shares, accounting for 0.35% of the company's issued share value.
many pharmaceutical companies have spent more than 100 million dollars on buybacks during the year, and many pharmaceutical companies have already spent more than 100 million yuan.
For example, Lizhu Pharmaceuticals has announced that as of August 31, 2020, the Company has repurchased a total of 5.9461 million shares of the Company's A-shares through centralized bidding transactions, accounting for the total share value issued by the Company as of August 31, 2020. 0.63% and 0.95% of the total number of A-shares issued, purchased at a high price of RMB 44.88 per share and at a low price of RMB38.95 per share, with a total of RMB243 million in funds used.
as of August 31, 2020, the cumulative number of shares repurchased by the Company through centralized bidding transactions was 14.575932 million shares, accounting for 1.08% of the Company's total share value, according to the company's announcement. , the transaction to the low price of 12.39 yuan / share, the transaction to the high price of 14.28 yuan / share, the cumulative total amount paid about 200 million yuan (excluding transaction costs), the repurchase progress in line with the relevant laws and regulations and the company's share repurchase program requirements.
have started a second round of buybacks it is worth noting that some pharmaceutical companies also opened a second round of buybacks.
For example, in June, Jincheng Pharmaceuticals announced that, in view of the expiration of the company's second repurchase program period on June 18, 2020, in order to fulfill the repurchase commitment, the company intends to implement a third share repurchase to complete the second share repurchase program related to the repurchase of funds commitments.
the total amount of the repurchase funds shall not be less than 30 million yuan, not more than 45 million yuan, and the repurchase price shall not exceed 35 yuan per share.
buy-back period shall be within 6 months from the date of consideration and adoption of the share repurchase plan by the general meeting of shareholders.
data show that Jincheng Pharmaceutical's main business is the research and development, production and sales of cephalosporine antibiotic pharmaceutical intermediates, and the layout of its entire industrial chain has been expanding through mergers and acquisitions, investment, extending to preparations and other fields.
this, market participants believe that the current share price has exceeded the price ceiling of the repurchase program, listed companies adjust the share price cap to continue to implement repurchase, showing full confidence in the company's performance and in-house value.